$ORY #Oryzon Genomics Oryzon Genomics - More data support vafidemstat for aggression: On 3 April 2020, Oryzon reported interim data for the first time from its two Phase IIa trials REIMAGINE-AD and ETHERAL. Both explore the company’s lead… https://t.co/XTBrmP2Q9H #equity #stocks https://t.co/8bPK9ANj03